Artificial intelligence continues to advance at an astonishing pace. We have tools that can process millions of tokens at once, scan vast repositories of information and generate responses that sound ...
Pharmaceutical marketers find themselves navigating an unprecedented regulatory moment. The Federal Trade Commission (FTC) launched “Operation AI Comply” in September 2024, bringing enforcement ...
Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd.
2026 will be the year for pharma marketers to move from AI experimentation to holistic integration. Pharma has been slower to adapt fully AI-generated commercials, with many marketers emphasizing the ...
To obtain a systematic view of Pharma.AI, the generative AI-driven solution for drug discovery and more cutting-edge research, please refer to the following answers provided by the Insilico AI team.
Nagesh Nama, CEO, xLM. Nagesh Nama is a seasoned technology executive with over 30 years of experience in life sciences. The release of the European Medicines Agency's Annex 22 on artificial ...
As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science.
As the AI era becomes increasingly shaped by foundation models, the pharmaceutical industry is entering a new phase of opportunity for discovery, design, and decision-making driven by AI for science.
“AI is now the first place people go to for answers,” according to Jesse Wolfersberger, global lead of I/O Health at Weber Shandwick. “That chat box is the most important battleground in health—brand ...
In this executive interview, Rebecca Willumson, publisher of Fierce Pharma, speaks with Jose Ferreira, chief product officer at CMI Media Group, about how AI is actively reshaping pharmaceutical ...
The potential harm of bias in generative AI tools is largely due to widespread adoption by organizations and free or low-cost ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results